Insights

Antibody-based drug discovery at the speed of light

icons/content-types/white paper white paper

Biologics Discovery

The combination of the PentaMice® platform and single B cell screening with the Berkeley Lights Beacon® Optofluidic system increases speed to market for monoclonal antibody therapeutics.

The Beacon® system is an innovative package using the technology of light, nanofluidics and refined AI algorithms to identify and orchestrate the movement of single B cells into a grid of NanoPen™ chambers for screening.

Download our white paper for insights on:

  • First-to-Human antibody therapeutics
  • Immunization — PentaMice® platform for antibody generation
  • Single B cell screening with the Beacon® system
  • Sequence Identification
  • Custom Bioinformatics
  • Case Study: Discovery of diverse monoclonal antibodies that bind SARS-CoV-2 Delta and Omicron spike proteins
    Gene-to-Protein Strategies

Download the White Paper

Ready to move from idea to impact?

Whether you have a question for our team or an opportunity you’re eager to pursue, one of our experts can help you get started.

Contact Us
More from Curia

040E93C7-D189-4233-A102-58C0580BE529 publications patents

Poster: In Vitro Characterization of a Dual Antagonistic Anti-LILRB2/LILRB4 Monoclonal Antibody

We have identified a dual antiLILRB2/LILRB4 antagonist. Targeting MDSCs with this antibody offers great promise for immunotherapy for cancer as well as its immense potential for synergy with PD-1 blockade.

icons/content-types/article article

Trends and Challenges in the Pharmaceutical Industry

Significant changes have taken place in the life sciences industry over the past few years. Since the Covid-19 pandemic, the U.S. government has urged biotech and pharmaceutical companies to increase domestic production in order to secure the drug su...